Oksazolidinonlara ve Daptomisine Direnç Mekanizmaları

Usluer G, Linezolid. Wilke Topçu A, Söyletir G, Doğanay M (Ed), Enfeksiyon Hastalıkları ve Mikrobiyolojisi, İstanbul, Nobel Tıp Kitabevleri;2017; sayfa : 325-327

Ntokou E. Vester B , Resistance to linezolid , Douglas L. M (Ed ) , Antimicrobial Drug Resistance Mechanisms of Drug Resistance, 2nd ed. Springer ; 2017 ; page:319-332

Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. The Lancet. 2001;358(9277):207–8. doi:10.1016/S0140-6736(01)05410-1. S0140-6736(01)05410-1 [pii]

Arias CA, Vallejo M, Reyes J et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. Journal of Clinical Microbiology. 2008;46(3):892–896. doi:10.1128/JCM.01886-07. JCM.01886-07 [pii].

Swoboda S, Fritz S, Martignoni ME et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. Journal of Antimicrobial Chemotherapy. 2005;56(4):787–9. doi:10.1093/jac/dki318

Stefani S, Bongiorno D, Mongelli G et al. Linezolid resistance in Staphylococci, Pharmaceuticals,2010,3(7).1998-2006;https://doi.org/10.3390/ph3071988

Miller K, Dunsmore CJ, Fishwick CW et al. Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrobial Agents and Chemotherapy. 2008;52(5):1737–42. doi:10.1128/AAC. 01015-07. AAC.01015-07 [pii].

Bendel JK, Cattoir V , Hegstad C, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug ResistanceUpdates.2018;40:25-39 .doi:10.1016/j.drup.2018.10.002

LiuY, Wang Y, Wu C, et al. First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin, Antimicrobial Agents and Chemotherapy. 2012;56(3): 1650-1654.doi:10.1128/AAC.06091-11

Almeida LM, Gaca A, Bispo PM, et al. Coexistence of the Oxazolidinone Resistance Associated Genes cfr and optrA in Enterococcus faecalis From a Healthy Piglet in Brazil. Frontiers in Public Health. 2020;24(8):518. doi: 10.3389/fpubh.2020.00518

Mendes RE, Deshpande LM, Castanheira M, et al. Evolving linezolid resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY antimicrobial surveillance program. Journal of Antimicrobial Chemotherapy.2018;73(9):2314/2322. https://doi.org/10.1093/jac/dky188

Bender JK, Fleige C, Lange D, et al. Rapid emergence of highly variable and transferable oxazolidinone and phenicol resistance gene optrA in German Enterococcus spp. clinical isolates, International Journal of Antimicrobial Agents . 2018;52(6): 819-827. doi:10.1016/j.ijantimicag.2018.09.009

Cavaco LM, Korsgaard H, Kaas RS, et al. First detection of linezolid resistance due to the optrA gene in enterococci isolated from food products in Denmark, Journal of Global Antimicrobial Resistance ,2017; 9 :128-129. doi:10.1016/j.jgar.2017.04.001

Mendes RE, Hogan PA, Jones RN, et al. Surveillance for linezolid resistance via the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. Journal of Antimicrobial and Chemotherapy. 2016;71(7): 1860-1865. doi:10.1093/jac/dkw052

Klare I, Fleige C, Geringer U et al. Increased frequency of linezolid resistance among clinical Enterococcus faecium isolates from German hospital patients. Journal of Global Antimicrobial Resistance.2015;3(2): 128-131. https://doi.org/10.1016/j.jgar.2015.02.007

Arman D, Sezer B.E, Lipopeptit Antibiyotikler, Wilke Topçu A (Ed), Enfeksiyon Hastalıkları ve Mikrobiyolojisi. İstanbul, Nobel Tıp Kitabevleri; 2017:sayfa:320

Nannini E, Murray E.B. Arias A.C. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Current Opinion in Pharmacolgy.2010;10(5):516-521. doi:10.1016/j.coph.2010.06.006

Capone A , Cafiso V , Campanile F, et al. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides. Europan Journal of Clinical Microbiology and Infection Dissease. 2016 ;35(4):625-31.doi:10.1007/s10096-016-2581-4

The European Committee on Antimicrobial Susceptibility Testing ( EUCAST). Clinical breakpoints - breakpoints and guidance. Available from:https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.xlsx. (Accessed 15th December 2022).

Shariati A, Dadashi M, Chegini Z, et al. The global prevalence of daptomycin, Tigecycline, Quinupristin/Dalfopristin, and linezolid-resistant Staphylococcus aureus and coagulase–negative staphylococci strains: a systematic review and meta-analysis. Antimicrobial Resistance and Infection Control. 2020;9: 56. doi: 10.1186/s13756-020-00714-9

Shukla BS, Shelburne S, Reyes K, et al. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With daptomycin: Is it Time to Change the Breakpoint? Clinical Infection Diseases. 2016;62: 1514-1520.doi:10.1093/cid/ciw173

Bender JK, Cattoir V , Hegstad C, at al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resistance Updates. 2018;40:25-38. doi:10.1016/j.drup.2018.10.002

Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci. The New England Journal of Medicine. 2011;365(10): 892-900. doi:10.1056/NEJMoa1011138

Mishra NN, Bayer AS, Tran TT, et al. daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS One, 7 (2012), p. e43958. doi: 10.1371/journal.pone.0043958

Steed ME, Vidaillac C, Rose WE, et al. Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial Agents Chemotherapy. 2011;55: 4748-4754. doi:10.1128/AAC.00084-11

Miller WR, Munita JM, Arias CA, et al. Mechanisms of antibiotic resistance in enterococci. Expert Review of Anti-infective Therapy.2014;12(10):1221-1236. doi: 10.1586/14787210.2014.956092

Panesso D, Reyes J, Gaston EP, et al. Deletion of liaR reverses daptomycin resistance in Enterococcus faecium independent of the genetic background. Antimicrobial Agents and Chemotherapy. 2015;59(12): 7327-7334.doi:10.1128/AAC.01073-15

Diaz L, Tran TT, Munita JM, et al. Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs. Antimicrobial Agents of Chemotherapy. 2014;58(8): 4527-4534. doi:10.1128/AAC.02686-14

Tran TT, Munita JM, Arias CA, et al. Mechanisms of drug resistance: daptomycin resistance. Annals of the New York Academy of Sciences. 2015;1354: 32-53. doi:10.1111/nyas.12948

Tran TT, Panesso D, Gao H, et al. Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrobial Agents and Chemotherapy. 2013;57(1): 261-268. doi:10.1128/AAC.01454-12

Sinel C, Jaussaud C, Auzou M, et al. Mutant prevention concentrations of daptomycin for Enterococcus faecium clinical isolates. International Journal of Antimicrobial Agents. 2016;48: 449-452. doi:10.1016/j.ijantimicag.2016.07.006

Werth BJ, Steed ME, Ireland CE, et al. Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. Faecalis. Antimicrobial Agents and Chemotherapy.2014;58(9): 5253-5261. doi:10.1128/AAC.00098-14

Mollerup S, Elmeskov C, Gumpert H, et al. Rapid in vivo development of resistance to daptomycin in vancomycin-resistant Enterococcus faecium due to genomic rearrangements. FEMS Microbiology Letters. 2022;369(1):fnac063. doi:10.1093/femsle/fnac063

Honsa ES, Cooper VS, Mhaissen MN, et al. RelA mutant Enterococcus faecium with multiantibiotic tolerance arising in an immunocompromised host, American Society for Microbiology,MBio.2017;8(1):e02124-16. doi:10.1128/mBio.02124-16

Matono T, Hayakawa K, Hirai R, et al. Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy. BMC Research Notes. 2016;9:197.doi:10.1186/s13104-016-2003-9

Munita JM, Tran TT, Diaz L, et al. A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrobial Agents and Chemotherapy.2013;57(6): 2831-2833. doi:10.1128/AAC.00021-13

Reyes J, Panesso D, Tran TT, et al. A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis. Journal of Infectious Diseases. 2015;211(8): 1317-1325. doi:10.1093/infdis/jiu602

Tran TT, Panesso D, Mishra NN, et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. American Society for Microbiology, MBio. 2013;4(4):e00281-13.doi:10.1128/mBio.00281-13

Miller C, Kong J, Tran TT, et al. Adaptation of Enterococcus faecalis to daptomycin reveals an ordered progression to resistance. Antimicrobial Agents and Chemotherapy.2013;57(11): 5373-5383. doi:10.1128/AAC.01473-13

Wang X, Davlieva M, Reyes J, et al. A novel phosphodiesterase of the GdpP family modulates cyclic di-AMP levels in response to cell membrane stress in daptomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy. 2017;61(3):e01422-16. doi:10.1128/AAC.01422-16

Palmer KL, Daniel A, Hardy C, et al. Genetic basis for daptomycin resistance in enterococci. Antimicrobial Agents and Chemotherapy. 2011;55(7): 3345-3356. doi:10.1128/AAC.00207-11

Pericas JM, Garcia-de-la-Maria C, Brunet M, et al. Hospital Clinic Endocarditis Study, Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis. Journal of Antimicrobial Chemotherapy. 2017;72(6): 1714-1722. doi:10.1093/jac/dkx016